📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Rifaximin-a reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. (2022)

First Author: Patel VC

Attributed to: Restoring innate immunity in cirrhosis with faecal microbial transplantation funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jhep.2021.09.010

PubMed Identifier: 34571050

Publication URI: http://europepmc.org/abstract/MED/34571050

Type: Journal Article/Review

Volume: 76

Parent Publication: Journal of hepatology

Issue: 2

ISSN: 0168-8278